ArticleGlobal medical genetics2026
Regulatory role and subtype analysis of m6A modifications in dermatomyositis.
Article in Global medical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dermatomyositis (DM) is an uncommon autoimmune disease that presents challenges due to the lack of reliable biomarkers in clinical practice. Growing evidence suggests that N6-methyladenosine (m6A) is closely associated with the pathogenesis of autoimmune diseases. Methods: Microarray gene expression matrix for GSE46239, GSE128314, and GSE142807 were downloaded from the GEO database. Random forest (RF), support vector machine (SVM), and nomogram models were developed, with their performance subsequently compared. The identification of m6A subtypes, based on differentially expressed m6A regulatory genes, was followed by the classification of gene subtypes according to the differently expressed genes between the m6A subtypes. Both classification systems were subjected to m6A scoring analysis and visualized via a Sankey diagram. Results: We retrieved 99 dermatomyositis samples and 14 healthy samples. Using an RF model, we identified five core genes-IGFBP3, ZCCHC4, HNRNPC, WTAP, and RBM15-and constructed a predictive nomogram model. Two m6A clusters were developed. Cluster A exhibited a significant increase of CD56-bright natural killer cells, immature B cells, plasmacytoid dendritic cells, regulatory T cells, and type 1 T helper cells distinct from cluster B (p < 0.05). Based on 32 significantly distinctly expressed genes between m6A subtypes (p < 0.05), we further reproduced two m6A gene subtypes. The Sankey diagram showed significant concordance among m6A scores, m6A subtypes, and m6A gene subtypes. Conclusion: m6A regulatory genes significantly influence the pathogenesis of dermatomyositis. In this work, we built a predictive nomogram model, comprehensively evaluated two classification methods, and provided new insights for patient classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.